What TECNIS Odyssey is
Odyssey is a diffractive full-range IOL from Johnson & Johnson, introduced in the United States in 2024. It is designed to cover distance, intermediate and near. The company says its shallower echelette steps reduce light scatter compared with earlier TECNIS multifocal designs. That is a design claim; the patient question is whether robust comparative trials show fewer disturbing halos without giving up range.
Non-toric and toric versions are available. J&J reported more than 100,000 implants by late 2025, but implant count is not a measure of effectiveness.
What it looks like
Odyssey's echelette optic is a proprietary design. We'd previously checked the FDA's public filings, the manufacturer's newsroom and press pages, distributor listings, and the open peer-reviewed literature, and found no independently published photograph — the only real product photography we could find lived behind the manufacturer's professional-only portal, restricted to healthcare providers. The photo above is different: it's Johnson & Johnson's own product photography, released publicly through its official press materials for the Odyssey launch rather than that professional-only portal. Worth noting plainly — this is a manufacturer-supplied image, not an independent one, so it shows the lens as the company chose to present it.
Where the data on this page comes from
This is worth stating plainly, because it's different from the other reviews on this site. TECNIS PureSee, Synergy, PanOptix, and Vivity were each approved under an FDA PMA supplement that came with a published Summary of Safety and Effectiveness Data (SSED) — a public document containing the full randomized registration-trial tables. Odyssey has also been through FDA PMA review (as a supplement under P980040, the same TECNIS platform approval), but as of this writing, FDA has not published a standalone SSED document with clinical trial tables specifically for Odyssey the way it has for those four lenses.
In place of that, the figures below come from two peer-reviewed retrospective studies published in Clinical Ophthalmology in 2026: 30 patients in a general cataract cohort and 26 selected patients with mild-to-moderate primary open-angle glaucoma. Both were investigator-initiated and funded by Johnson & Johnson grants, with conflicts disclosed. They can be checked by readers, unlike internal “Data on File,” but they are not independent of manufacturer funding and they are not substitutes for a large randomized registration trial.
Visual acuity across two small studies
Both studies measured the percentage of patients reaching a threshold level of uncorrected and corrected acuity at distance and at 40 cm near. Note that the two studies used different acuity thresholds (20/20 in the general cohort, 20/25 in the glaucoma cohort) — shown here exactly as each study reported it, not adjusted to a common scale.
Both studies reported that all eyes landed within ±0.5 D of intended spherical-equivalent correction and residual astigmatism. In such small cohorts, 100% means 60 and 52 eyes, not a guarantee for the next patient. Neither study published a defocus curve, so these two papers do not map the full intermediate range between distance and the single 40 cm near test.
Spectacle independence at near
Both studies asked whether patients still needed glasses for near tasks after surgery — a more direct, patient-relevant measure than acuity alone.
These figures come from patients' self-reports rather than a standardized, validated questionnaire (such as the PRVSQv2 instrument used in some FDA registration trials) — both papers note this explicitly as a limitation of their own methodology.
Halos, and what's missing from this picture
Dysphotopsia means unwanted light phenomena such as halos, glare and starbursts. For this diffractive lens, the important question is what patients reported and how the study asked. The two available studies leave much of that question unanswered.
Neither study reported separate glare or starburst rates, neither used a validated dysphotopsia questionnaire, and neither collected contrast sensitivity data at all — a real gap for a lens whose whole design rationale (shallower echelette steps) is specifically about reducing light scatter compared with earlier diffractive designs. The manufacturer's own "Data on File" figures (93% reporting no or only mild dysphotopsia symptoms) may turn out to be broadly consistent with the picture here, but that specific claim has not been independently published in a form this page can verify.
Possible limitations, based on this data
- No FDA SSED with full registration-trial tables has been published for Odyssey as of this writing — the two studies used here are smaller, shorter, and industry-funded, not the large randomized trial data available for PureSee, Synergy, PanOptix, and Vivity on this site.
- Both studies are short-term (44 and 68 days average follow-up) and single-site — there is not yet independently published data on Odyssey outcomes at 6 or 12 months.
- Neither study reported contrast sensitivity or a defocus curve — meaning there's no independently verified picture of intermediate-distance performance or low-light contrast trade-offs for this lens yet.
- Spectacle-independence and halo figures came from unstructured patient self-report, not a validated questionnaire, in both studies.
- One study enrolled only patients with mild-to-moderate glaucoma, so its results may not apply to typical cataract patients. The reverse is also true: a general cataract study does not automatically describe what people with glaucoma will experience.
- Both studies were funded by an investigator-initiated grant from Johnson & Johnson, the lens's manufacturer — peer-reviewed and disclosed, but not fully independent of the company with a commercial interest in the result.
Who this lens may suit
Odyssey is reasonable to discuss if near-to-far glasses independence is a high priority and you accept that fewer and smaller studies are available than for established alternatives. The small glaucoma study is an early finding worth following, not permission to generalize the lens to glaucoma. Disease stage, field loss, progression and baseline contrast still require an individual glaucoma and cataract assessment.
How it compares
Odyssey sits in the same broad full-range/diffractive-EDOF category as TECNIS Synergy and Alcon PanOptix, aiming to reduce spectacle dependence across all three distances. Its newer echelette geometry is intended to lower halo and glare rates, but this page cannot yet verify that claim against the public, larger registration-trial datasets available for those established lenses. For the broader category comparison, see Full Range / Trifocal IOLs.
Questions for your surgeon
- Which Odyssey outcome comes from a randomized comparison rather than a small case series?
- How were halos, glare and starbursts asked about, and was the questionnaire validated?
- What do your patients use glasses for at 33, 40 and 60–66 cm?
- If I have glaucoma, what is my stage and baseline contrast sensitivity, and why does that make this lens suitable?
A note on this review
This page is educational content, not a personal recommendation. The figures come from two peer-reviewed, manufacturer-grant-funded studies. Their small samples, short follow-up and non-validated symptom collection remain visible because those limitations change how confidently the results can be applied.
Sources: Clinical outcomes in Japanese eyes, Clinical Ophthalmology 2026;20:610351; clinical outcomes in selected patients with primary open-angle glaucoma, Clinical Ophthalmology 2026;20:616773.